Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

NCT06577519

Status	RECRUITING
Phase	Phase 3
Sponsor	Jiangsu vcare pharmaceutical technology co., LTD
Enrollment	1,000 participants

Key Eligibility Criteria

Inclusion (3)

- Patients between 18 and 80 years old, with no gender restrictions.
- Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA/NSTEMI).
- Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period.

Exclusion (4)

- Expected survival time\<12 months;
- Severe liver dysfunction (non heart disease induced ALT or AST\>3x ULN) and cirrhosis;
- Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period;
- The researchers determined that other reasons were not suitable for participants in this experiment.

Locations (1 total)

General Hospital of Northern Theater Command of Chinese PLA, Shenyang, Liaoning, China